NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Keros Therapeutics, Inc. (KROS) Stock Analysis

Keros Therapeutics, Inc. (KROS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

KROS

$11.32

+$0.21 (+1.89%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KROS with… →

KROS Key Statistics

As of Sep 4, 2026
Trading
Open
$11.03
Previous Close
$11.11
Day's Range
11.02–11.40
52-Week Range
9.69–22.55
Volume
65.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.02
Valuation
Market Cap
$224.44M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
14.95
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.28
Financials (FY)
Revenue (FY)
$244.06M+6774.96%
Net Income (FY)
$87.01M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
19.83M
1-Year Return
−27.20%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
241.03K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

KROS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−44.40%
2025+28.62%
2024−60.19%
2023−17.20%
2022−17.93%
2021−17.05%
2020 (partial year)+251.29%

As of September 4, 2026.

KROS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$244.06M$87.01M35.7%
2024$3.55M−$187.35M−5277.5%
2023$151.00K−$152.99M−101319.2%
2022$0.00−$104.68M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$244.06M—$67.57M$87.01M35.7%
2024$3.55M—−$209.60M−$187.35M−5277.5%
2023$151.00K—−$167.54M−$152.99M−101319.2%
2022$0.00—−$107.71M−$104.68M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

KROS Valuation vs Biotechnology Median

Median of 656 stocks
MetricKROSBiotechnology medianvs median
P/S ratio14.9515.262% below
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Keros Therapeutics, Inc. (KROS) carries a market capitalisation of $224.44M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 92 employees.

The 52-week range on file runs from $9.69 to $22.55. KROS last closed at $11.32 on September 4, 2026. That is +$0.21 (+1.89%) against the previous close. The latest close sits 16.82% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $244.06M. That is +6,774.96% against the prior fiscal year, when revenue was $3.55M. The same year closed with net income of $87.01M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −3.28.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $244.06M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 14.95. On price-to-sales that is 2.06% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is −27.20%. Measured over 5 years, that is −19.18% a year compounded. The reported beta is 1.02. Daily returns over the trailing 6 years annualize to a volatility of 67.72%.

Growth & Income

The record shows no dividend for KROS.

Across the complete calendar years on file, 2025 returned +28.62% and 2024 returned −60.19%. Of the 5 complete calendar years on file, 1 finished higher. 2026 is still running; the price is −44.40% year to date.

Peer Comparison

Keros Therapeutics, Inc. (KROS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Keros Therapeutics, Inc. KROS $224.44M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Keros Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Keros Therapeutics, Inc.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Visit website →